Bonanni E, Massetani R, Galli R, Gneri C, Petri M, Iudice A, Murri L
Department of Neurosciences, University of Pisa, Italy.
Acta Neurol Scand. 1997 Apr;95(4):193-6. doi: 10.1111/j.1600-0404.1997.tb00097.x.
The clinical relevance of daytime sleepiness associated with carbamazepine (CBZ) and vigabatrin (VGB) was objectively assessed by the multiple sleep latency test (MSLT) and nocturnal sleep recordings.
Twenty-six patients with partial epilepsy and mean monthly seizure frequency of 4, aged 18 to 48 years, receiving chronic monotherapy with CBZ and subsequent VGB addition for 2 months (14 patients), were compared with a group of healthy subjects. Subjective daytime sleepiness was complained by 13 patients on CBZ monotherapy and 9 patients during VGB add-on treatment.
No differences in nocturnal sleep parameters, but significantly shorter daytime sleep latencies at the MSLT, were detected in CBZ-treated patients as compared with healthy controls. Addition of VGB therapy did not further enhance objective daytime sleepiness.
Some sleepiness occurs in chronically CBZ-treated epileptic patients, which can be objectively measured by the MSLT, but it is not aggravated by add-on VGB.
通过多次睡眠潜伏期试验（MSLT）和夜间睡眠记录，客观评估了与卡马西平（CBZ）和vigabatrin（VGB）相关的日间嗜睡的临床相关性。
将26例部分性癫痫患者（年龄18至48岁，平均每月癫痫发作频率为4次，接受CBZ慢性单一疗法治疗，随后添加VGB治疗2个月，共14例患者）与一组健康受试者进行比较。13例接受CBZ单一疗法治疗的患者和9例在添加VGB治疗期间的患者主诉有主观日间嗜睡。
与健康对照组相比，CBZ治疗的患者夜间睡眠参数无差异，但MSLT的日间睡眠潜伏期显著缩短。添加VGB治疗并未进一步加重客观日间嗜睡。
长期接受CBZ治疗的癫痫患者会出现一些嗜睡情况，可通过MSLT客观测量，但添加VGB不会使其加重。
